CHARLOTTE, NC
Crohn’s Disease Clinical Trials
8 studies are enrolling for Crohn’s disease near Charlotte NC right now. Notably, two of them give every person a drug that is already approved, and one takes children. You may be compensated for your time, and no insurance is needed.
8
Open Near Charlotte
2
With No Dummy
+/- $100
Per Visit
New here? Read how this page works
First, two numbers decide which of these will take you, and most people have never been told either. So here is the order to work through.
- Ask for your CDAI score in writing. Because nearly every study here gates on it, and most want 220 to 450.
- Ask for your camera score separately. Notably, most want a 6, or a 4 if only the last part of the small bowel is involved.
- Ask for a faecal calprotectin. In fact, it measures swelling in the gut specifically, and a normal blood test does not rule out a flare.
- Finally, tap the button. Then we check you against all of them at once and tell you when a new one opens.
Of course, checking never signs you up for anything. You are only seeing where you might fit.
The 8 Studies Enrolling Near Charlotte Right Now
Every one of them is open today. So check your eligibility, or read the full record on ClinicalTrials.gov.
The two with no dummy anywhere in them
Both give every person a drug that is already approved. So if the dummy question is what is stopping you, start here.
Two Approved Drugs, Head to Head
Janssen / Approved drug comparison
Both drugs in this one are already approved and on the market. So the question is which works better, not whether either works. You would know which one you are on, because it is open label. Both are pens you inject yourself. Notably, there is no dummy anywhere in it.
Payment is not published.
Check eligibility →More details
Why researchers are excited: nobody has properly compared these two against each other before. Meanwhile, doctors currently choose between them on habit and insurance rather than evidence.
Who this study is looking for
- Crohn’s for at least 12 weeks, in the colon, the ileum or both
- Also, A CDAI score between 220 and 450
- Besides that, visible ulcers on the camera test, scored 4 or 6 depending on where
- Finally, confirmed by scan, tissue sample or camera
Probably not a fit if: a draining stoma rules you out. Also, significant tunnelling disease or a narrowing that causes symptoms. Notably, if both of these drugs have already failed you, this study has nothing to offer.
- Placebo group: None. Both arms get a licensed drug, and you know which one.
- How long: The main answer comes at week 52. However, checks continue past three years.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A camera test of the bowel is required. Two are needed, at the start and at week 52, both read centrally.
- Setting: Outpatient.
- Where it runs: Charlotte Gastroenterology and Hepatology, Charlotte NC 28207.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- The bar for success here is high. It counts only if your symptoms settle and the camera score drops. So ask what happens if you get halfway.
- Full study record: View on ClinicalTrials.gov →
An Approved Drug, in an Ordinary Clinic
Takeda / Approved drug study
This does not test whether the drug works. That is settled, because it is approved already. Instead it looks at using it in ordinary community clinics rather than big centres. You get drips for six weeks, then a pen you use yourself. So everyone here receives a licensed treatment.
Payment is not published.
Check eligibility →More details
Why researchers are excited: most studies run at academic hospitals. However, this one runs where most people actually get their care.
Who this study is looking for
- Age 18 to 80, with a CDAI score of 220 to 450
- Also, A camera score of 6, or 4 if only the ileum is involved
- Besides that, steroids or newer drugs failed, stopped working, or were not tolerated
- Finally, vaccinations up to date for this drug
Probably not a fit if: any past use of this drug family rules you out for good. That means ever, not recently. Also, more than two failed newer drugs excludes you, and so does a stoma or short bowel.
- Placebo group: None. Everyone gets the approved drug.
- How long: About a year of treatment. Then a final check about 18 weeks after the last dose.
- Clinic visits: Several across the year, with set checks at weeks 6, 14, 26 and 52.
- Phone calls: Not published on the public record.
- Most invasive part: A camera test of the bowel is required. Two are needed, at the start and at week 52.
- Setting: Outpatient.
- Where it runs: Charlotte Gastroenterology and Hepatology, Charlotte NC 28207; Piedmont Healthcare, Statesville NC 28625.
- Drive from Charlotte: One site is in the city and the other is at Statesville, about 40 minutes north.
- Check your records first. Any anti-integrin drug ever taken rules you out. So look for vedolizumab or natalizumab before you call.
- Full study record: View on ClinicalTrials.gov →
The five testing a new drug against a dummy
None of these drugs is approved yet. However, three of them chase a target that no approved drug touches at all.
The One Study Running in Both Cities
Sanofi with Teva / Late stage antibody
Duvakitug blocks a signal called TL1A. Researchers think it drives the scarring that causes narrowings. Notably, no approved drug for this targets scarring at all. That matters more in Crohn’s than anywhere else, because narrowings lead to surgery. This is the only Crohn’s study here with sites in both metros.
Payment is not published.
Check eligibility →More details
Why researchers are excited: narrowing and scarring send people to the operating theatre. Meanwhile, every approved drug treats swelling and leaves the scarring alone.
Who this study is looking for
- Age 18 to 80, with Crohn’s confirmed at least 3 months ago
- Also, moderate to severe disease
- Besides that, usual or newer drugs failed, stopped working, or were not tolerated
- Finally, A steady dose of your current medicine going in
Probably not a fit if: colitis or an undecided diagnosis rules you out. Also, missing two whole sections of bowel from past surgery. Notably, any earlier anti-TL1A drug excludes you for good.
- Placebo group: Yes in the main part, though one sub study is open label with no dummy at all.
- How long: Up to 35 weeks, counting screening, 12 weeks of treatment and possibly 12 more.
- Clinic visits: Up to 8 visits, or up to 15 if you go into the extended part.
- Phone calls: Not published on the public record.
- Most invasive part: A camera test of the bowel is required. At least two, and you must complete the second to continue.
- Setting: Outpatient.
- Where it runs: OnSite Clinical Solutions, Charlotte NC 28211; Monroe Biomedical Research, Monroe NC 28112; Biocentric Health Research Partner, West Columbia SC 29169.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Ask what happens after week 12. The follow on study has no site in either metro.
- Full study record: View on ClinicalTrials.gov →
A Pill Instead of an Injection
Janssen / Late stage tablet
Nearly every modern drug for this is an injection or a drip. However, this one is a pill you swallow. It blocks the same IL-23 target the injected drugs hit. So the question is whether a tablet can match a needle. It is the largest study on this page.
Payment is not published.
Check eligibility →More details
Why researchers are excited: a tablet that works as well as an injection changes daily life rather than just outcomes. Also, this is the first of its kind to reach this stage.
Who this study is looking for
- Crohn’s confirmed at least 12 weeks ago, by camera and sample
- Also, A CDAI score of 220 to 450
- Besides that, either four loose stools a day or real abdominal pain
- Finally, A camera score of 6, or 4 if only the ileum is involved
Probably not a fit if: a stoma bag rules you out. Also, a narrowing that causes symptoms, or short bowel. However, an active tunnel is allowed here if no surgery is needed, which is unusual.
- Placebo group: Yes. It is blinded against a dummy, and the split is not published.
- How long: The main answer comes in September 2028. Meanwhile, the record runs to 2032.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A camera test of the bowel is required. The first is filmed and read by a central team.
- Setting: Outpatient.
- Where it runs: Atrium Health, Charlotte NC 28204.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- The Rock Hill site has closed. Only the Charlotte site is open, so ask for Atrium Health by name.
- Full study record: View on ClinicalTrials.gov →
The Shortest Commitment on This Page
Roche with Chugai / Late stage antibody
Afimkibart blocks the same TL1A signal as the study above. However, this version asks for the least time. The main answer comes at 12 weeks. To count as a success, both your symptoms and the camera score must move. So it is a harder bar but a shorter run.
Payment is not published.
Check eligibility →More details
Why researchers are excited: most late stage studies here ask for a year or more. Meanwhile, this one answers its question in 12 weeks.
Who this study is looking for
- Confirmed moderate to severe Crohn’s
- Also, age 16 to 80, weighing at least 40 kg
- Besides that, at least one usual or newer drug failed or was not tolerated
- Finally, willing to use contraception if it applies to you
Probably not a fit if: a stoma, a pouch or three past bowel operations rules you out. Also, complex tunnels with more than three openings. However, simpler tunnels are not automatically excluded.
- Placebo group: Yes. It is blinded against a dummy, and the split is not published.
- How long: The main answer comes at week 12. Meanwhile, safety checks run about 30 weeks.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A camera test of the bowel is required. Two are needed, at the start and at week 12.
- Setting: Outpatient.
- Where it runs: Charlotte Gastroenterology and Hepatology, Charlotte NC 28207.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Full study record: View on ClinicalTrials.gov →
The Same Drug, Carried Much Further
Roche / Late stage antibody
This is the same drug as the study above, run a different way. You stay on whatever you were first given, right through the long part. So if you respond, you keep going without being reassigned. However, if you are on the dummy, you are on it longer than in the shorter study. That trade is the whole difference between the two.
Payment is not published.
Check eligibility →More details
Why researchers are excited: staying on one assignment avoids the disruption of being switched mid study. Meanwhile, it also means a longer wait to find out which you were on.
Who this study is looking for
- Confirmed moderate to severe Crohn’s
- Also, age 16 to 80, weighing at least 40 kg
- Besides that, at least one usual or newer drug failed or was not tolerated
- Finally, no previous anti-TL1A drug of any kind
Probably not a fit if: a stoma, a pouch or three past bowel operations rules you out. Also, any confirmed pre cancerous change in the colon, which is stricter than its sister study. Notably, complex tunnels exclude you too.
- Placebo group: Yes, and you stay on your original assignment through the long part.
- How long: Treatment then maintenance, with the main completion due December 2028.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A camera test of the bowel is required. Expect more of them than in its shorter sister study.
- Setting: Outpatient.
- Where it runs: Atrium Health, Charlotte NC 28204; Monroe Biomedical Research, Monroe NC 28112.
- Drive from Charlotte: One site is in the city and the other is at Monroe, about 30 minutes south east.
- Compare the two Roche studies directly. Same drug, different lengths. So ask which one the site would put you in and why.
- Full study record: View on ClinicalTrials.gov →
The Furthest Along of the Three New Ones
Merck / Late stage antibody
Tulisokibart is the third drug here aimed at TL1A. It is the furthest along of the three. Both a drip version and a self injection version are being tested. So there are several dose levels and matching dummies. Whether you get a year or twelve weeks depends which half you enter.
Payment is not published.
Check eligibility →More details
Why researchers are excited: of the three drugs chasing this target, this one has the most data behind it. Also, testing both a drip and an injection means a real choice later.
Who this study is looking for
- Crohn’s diagnosed at least 3 months ago
- Also, moderate to severe disease
- Besides that, at least one named drug class failed or was not tolerated
- Finally, age 16 to 80
Probably not a fit if: a stoma, or needing one, rules you out. Also, disease only around the back passage or only high in the gut does not qualify. Notably, a narrowing a camera cannot pass through excludes you.
- Placebo group: Yes, with matching dummy drips or injections across several dose levels.
- How long: One half runs to week 52. Meanwhile, the other answers at week 12.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: A camera test of the bowel is required. Up to three, depending which half you enter.
- Setting: Outpatient.
- Where it runs: Atrium Health Gastroenterology MMP, Charlotte NC 28204.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- One Charlotte site has closed. The Tryon Medical site is finished. So ask for Atrium Health Gastroenterology by name.
- Full study record: View on ClinicalTrials.gov →
For children and teenagers
This is the only study for under 18s in either city. Notably, every child in it gets a real approved drug.
For Children and Teenagers, With No Dummy
Connecticut Children’s with the NIH / Approved drug study
This is the only study for children in either city. Everyone gets an approved drug, either an injection or a drip. The study tests a tool that reads drug levels and adjusts the dose. So the aim is getting the dose right sooner. Notably, a child can join before the diagnosis is even confirmed.
Payment is not published.
Check eligibility →More details
Why researchers are excited: children are usually the last group to get access to anything. Meanwhile, this one lets them in early and gives every child a real drug.
Who this study is looking for
- Age 6 to under 18
- Also, crohn’s suspected, and a confirmed diagnosis is not required to start
- Besides that, A negative stool test for infection
- Finally, both parent consent and the child’s own agreement
Probably not a fit if: being unable to tolerate an MRI scan rules a child out. Also, disease only around the back passage, the mouth or high in the gut. However, a seton or a drained abscess does not exclude, which surprises families.
- Placebo group: None. Every child gets an approved drug.
- How long: About 18 months for each child, inside a five year study.
- Clinic visits: Not published on the public record.
- Phone calls: Not published on the public record.
- Most invasive part: Two camera tests and two MRI scans. Also, tissue samples from two places are required. Notably, the bar it sets for success is the strictest on this page.
- Setting: Outpatient.
- Where it runs: Levine Children’s, Charlotte NC 28203.
- Drive from Charlotte: This one is inside Charlotte, so no satellite town drive is involved.
- Full study record: View on ClinicalTrials.gov →
Not sure which one fits you?
First, answer a few quick health questions. Then we check you against all 8 at once. Also, no account and no paperwork.
See if I may fit one of these studies →What Is Actually Changing in Crohn’s Disease
Two new drugs were approved in the last two years, and three more are chasing a target nobody has hit.
It Can Appear Anywhere, and in Patches
Crohn’s can affect anywhere from the mouth to the bottom, though it favours the last part of the small bowel. It appears in patches with healthy stretches in between. So those gaps are how a doctor tells it apart from colitis. Also, it goes through the entire thickness of the bowel wall.
That Depth Is Why the Complications Happen
Because it goes through the whole wall, it can create tunnels, pockets of infection and narrowings. Meanwhile, colitis stays in the lining and causes none of those. So the two diseases need different studies. In fact, an undecided diagnosis usually rules you out of both.
Surgery Does Not Cure It
In colitis, removing the large bowel ends the bowel disease. However, that is not true here. The disease usually comes back near the join. So the aim is to avoid surgery rather than to schedule it, and that is why speed matters.
Two Numbers Decide Whether a Study Will Take You
The first is CDAI, and moderate to severe means 220 to 450. The second is the camera score, usually written SES-CD. Most studies want 6, or 4 if only the ileum is involved. So ask for both in writing after your next camera test.
Ask for Faecal Calprotectin By Name
It is a stool test that measures swelling in the gut specifically. That makes it more useful than a general blood test. Notably, CRP can look normal while your bowel is inflamed. So a normal blood result should not end the conversation.
TL1A Is the Target Everyone Is Chasing
Three drugs on this page block the same signal, called TL1A. Researchers think it drives the scarring that leads to narrowings, and no approved drug touches scarring today. However, taking any one of the three rules you out of the other two for good. So mention any past study drug by name.
Icotrokinra: The Pill in a Field of Injections
Almost every modern drug here is a needle. So a tablet blocking the same target would change daily life rather than just outcomes. That is what the largest study on this page is testing. Also, it is the first of its kind to get this far.
Two Approvals That Changed the Options
Mirikizumab was approved for Crohn’s in January 2025, and guselkumab followed in March 2025. Both block IL-23. So people who had run out of options got two new ones inside three months. Meanwhile, that also raised the bar every newer drug now has to clear.
Crohn’s Disease Help Near You
Start with a gastroenterologist rather than a general clinic. Ask for your CDAI, your camera score and a faecal calprotectin in writing. Also, ask whether your last camera test was filmed, because studies often need a central team to read it. Generally, your own doctor can refer you.
Research Sites Near Charlotte
Six research sites across the metro carry these eight studies. But sites add new studies all the time, so it is worth knowing what sits near you.
Atrium Health
Multiple Charlotte locations / 161+ active studies
Crohn’s, Heart Failure, COPD, Dementia, Type 2 Diabetes, Hypertension
Charlotte’s biggest health system. It is tied to Wake Forest University School of Medicine. Also, it runs far more trials than anyone else nearby.
Visit Website →
American Health Research Network
Ballantyne, NC 28277 / 25 to 30+ active studies
Asthma, COPD, Chronic Cough, Type 2 Diabetes
Led by Dr. Selwyn Spangenthal. It is the biggest private lung research group in Charlotte. Specifically, it has 4 offices: Charlotte, Rock Hill, Lake Norman, and Charleston.
Visit Website →
Monroe Biomedical Research
Monroe, NC / 17+ active studies
Asthma, COPD, Hypertension, Obesity, Ulcerative Colitis
Notably, one of the 5 busiest research sites in the country. Its 6,300 sq ft space can host overnight stays. It is also an SCRS Global Impact Partner.
Visit Website →
Clinical Research of Gastonia
Gastonia, NC / 11+ active studies
Asthma, COPD, Chronic Cough, Idiopathic Hypersomnia
Led by Dr. Anup Banerjee. Its 3,500 sq ft space sits next to CaroMont Regional Medical Center. Also, it has been running for over 10 years.
Visit Website →
OnSite Clinical Solutions
Ballantyne, NC 28277 / 10+ active studies
Ulcerative Colitis, Crohn’s, COPD, Heart Failure, Atopic Dermatitis
It works with Charlotte doctors in heart, gut, skin, nerve, and joint care. Besides, it runs studies from Phase I through Phase IV.
Visit Website →
Flourish Research
Matthews, NC 28105 / 4+ active studies
Alzheimer’s Disease, Early Alzheimer’s, Alzheimer’s-Related Psychosis
Led by Dr. M. Reza Bolouri. He has 20+ years in Alzheimer’s research. The site is an Alzheimer’s Center of Excellence. In fact, its network has finished 5,500+ trials.
Visit Website →
New Hope Clinical Research
SouthPark, NC 28211 / 4+ active studies
Major Depression, Schizophrenia, Bipolar Disorder
Led by Dr. Kurian Abraham. It runs Phase I through IV studies and has 30 beds for overnight stays. Its last FDA audit came back clean. Also, it has finished 200+ brain studies.
Visit Website →
Queen City Clinical Research
SouthPark, NC 28211 / 2+ active studies
Chronic Pain, Chronic Migraine, Osteoarthritis
Led by Dr. Leonardo Kapural, a former Cleveland Clinic professor. Notably, he has written 200+ journal articles. On top of that, many call this the biggest pain research site in the country.
Visit Website →
Novant Health
Multiple Charlotte locations / Several active studies
Cardiovascular Disease, Obesity, Hypertension
One of the biggest health systems in the Carolinas. Its Heart and Vascular Institute runs heart studies and sees a lot of patients.
Visit Website →
DLVSC
4 Charlotte-area offices / 1+ active studies
Eczema, Psoriasis, Rosacea
Led by Dr. Gilly Munavalli. This award-winning skin practice owns 50+ FDA-approved lasers and devices. Also, it has its own research team.
Visit Website →
DelRicht Research
South Charlotte, NC 28210 / 1+ active studies
Bipolar Disorder, Bipolar Depression
Part of a national network of mental health research sites. Currently, it runs the azetukalner bipolar depression trial in Charlotte. Previously, it ran other mental health studies.
Visit Website →
TMS of the Carolinas
South Charlotte, NC 28210 / 1+ active studies
Major Depression, Treatment-Resistant Depression
A specialty site for brain stimulation care. It runs the fast TMS study that packs 6 weeks into 2.
Visit Website →What to Expect in a Crohn’s Disease Study
New to studies? Here is how one works, step by step.
01
Prescreening
First comes a short phone call or online form. Also, it takes about 10 to 15 minutes. The staff check whether you might fit. Then they tell you what is open.
02
Screening Visit
Next the clinic runs the tests that decide it, which usually means blood work. Also, they go through the consent form line by line, and you can bring somebody with you.
03
Treatment Period
Then the study begins. So you take the study drug or the placebo on the agreed schedule. Meanwhile, your own doctor keeps managing everything else.
04
Follow-Up
Finally, there is a check in period at the end. Also, your own doctor gets the results, and you can stop at any point without affecting your care.
Crohn’s Disease Trial FAQs
Real answers about Crohn’s disease studies near Charlotte NC.
Is there a study for this near Charlotte?
Yes, eight are open, spread across six clinics in the metro. Two of them have no dummy group at all, because every person gets a drug that is already approved. Meanwhile, five test drugs that are not approved yet, against a dummy. Notably, the eighth takes children aged 6 to 17, and it is the only one for under 18s in either city.
Will I get a dummy?
It depends which study, so ask this first rather than last. Some here have no dummy at all, because every person gets an approved drug. Meanwhile, others test a drug that is not approved yet against a dummy, and most do not publish the split. So ask the clinic what your odds actually are before you agree to anything.
Will I have to stop my current medicine?
Usually you must be on a steady dose rather than off everything, which surprises people. However, the exact wash out period is not published for most of these. One study does publish it, at thirty days or five half lives, whichever is longer. Notably, that same study can waive the wait if a blood test shows the old drug has cleared.
What is a CDAI score?
It is how active your disease is, in one number, and studies gate on it. It combines stool frequency, pain, general wellbeing and several other findings. Generally, 220 to 450 counts as moderate to severe, and that is the usual entry bar here. So ask for it in writing rather than accepting a description.
Do I have to have a colonoscopy?
Yes, and usually more than one. Most studies need one at the start and another at the end of the main period. Also, several are filmed and read by a central team rather than by your own doctor. So ask whether your last one was recorded, because an unrecorded test often has to be repeated.
Is it different from ulcerative colitis?
Yes, and studies will not mix them up. Crohn’s can appear anywhere from mouth to bottom, in patches, and it goes through the whole bowel wall. Meanwhile, colitis stays in the large bowel and rectum, in one unbroken stretch, and only in the lining. So that depth is why tunnels and narrowings happen here and not there.
What is this TL1A everyone mentions?
It is a signal that researchers think drives the scarring behind narrowings. Three separate drugs on this page block it, and no approved drug touches scarring at all. However, taking any one of the three rules you out of the other two permanently. So mention any past study drug by name when you call.
Can my child join a study?
In Charlotte, yes. One study takes children aged 6 to 17, and every child in it gets an approved drug. Notably, a child can join before the diagnosis is even confirmed. However, it needs two camera tests and two MRI scans, so a child who cannot manage an MRI is excluded. Meanwhile, nothing for under 18s runs in the Midlands.
Does it cost anything to check?
No. There is no cost, and no insurance is needed. Tether is a nonprofit list, so we do not run studies and we are not paid to send you anywhere. Also, checking never enrolls anyone in anything. You would always call the clinic yourself.
Where can I get help near Charlotte NC?
Atrium Health and Novant Health both run bowel services across the metro, and Charlotte Gastroenterology and Hepatology runs several of these studies. Levine Children’s runs the study for under 18s. Also, ask for a gastroenterologist rather than a general clinic. Generally, your own doctor can refer you. Meanwhile, if nobody has given you a CDAI score, ask for it by name at your next visit.
Ready to Explore a Study?
Check your eligibility, or just reach out to our Charlotte team. No pressure. Also, no sales pitch.
← Back to All Clinical TrialsSources
- CHARGE, guselkumab against risankizumab, ClinicalTrials.gov NCT07499232
- PANORAMA, vedolizumab in community clinics, ClinicalTrials.gov NCT06581328
- Duvakitug for Crohn’s disease, ClinicalTrials.gov NCT07184931
- Icotrokinra oral tablet for Crohn’s disease, ClinicalTrials.gov NCT07196722
- SIBERITE-2, afimkibart 12 week study, ClinicalTrials.gov NCT06819891
- SIBERITE-1, afimkibart treat through study, ClinicalTrials.gov NCT06819878
- Tulisokibart for Crohn’s disease, ClinicalTrials.gov NCT06430801
- CAMEO, anti-TNF dosing in children aged 6 to 17, ClinicalTrials.gov NCT05781152
- Target CD, AbbVie four arm platform study, ClinicalTrials.gov NCT06548542
- Mirikizumab approved for Crohn’s disease, 15 January 2025
- Guselkumab approved for Crohn’s disease, 20 March 2025
- Yale Medicine: monitoring inflammation and what mucosal healing means
Study details and per-site recruiting status verified against ClinicalTrials.gov on August 16, 2026. Every site row was read individually, because a study can read as recruiting while a particular clinic has closed. Two studies here list a nearby site as completed while the study overall still recruits. One study was absent from the public data export entirely and was found only by searching the city directly. Study availability and criteria change; the research clinic confirms everything before you enroll.